Skip to main content

Advertisement

SpringerLink
Log in

NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this study was to investigate neural precursor cell expressed developmentally down-regulated 9 (NEDD9) expression in human gastric carcinoma (GC) and to explore its clinic significance. NEDD9 expression was detected by immunohistochemistry in GC, their corresponding paracancerous histological normal tissues (PCHNTs), and gastric normal tissues. And this result was further confirmed at the protein and mRNA level by Western blotting and quantitative real-time PCR, respectively. The Kaplan–Meier method and log-rank test were employed to compare the overall survival between NEDD9 low-level expression group and NEDD9 high-level expression group. We ascertained frequently NEDD9 up-regulation in both protein and mRNA levels in GC tissues as compared to PCHNTs and normal controls. Immunohistochemical staining indicated that NEDD9 is higher expressed in GC tissues (102 out of 125, 81.8 %) than that in PCHNTs (eight out of 42, 19.05 %) and gastric normal tissues (one out of eight, 12.50 %). NEDD9 expression levels were closely associated with poor differentiation (P = 0.002), venous invasion (P = 0.012), invasive depth (P < 0.001), preset lymph node metastasis (P = 0.023), distant metastasis (P = 0.017), and high clinical stage (P = 0.005). NEDD9 expression was positively correlated with clinical tumor node metastasis (TNM) stage that implied the more advanced clinical TNM stage corresponding to the higher expression level of NEDD9 (r s = 0.467, P < 0.001). And we also detected frequently NEDD9 up-regulation in both protein and mRNA levels in GC tissues as compared to PCHNTs. Kaplan–Meier survival analysis showed that high NEDD9 expression exhibited a significant correlation with poor prognosis for gastric cancer patients. Our data suggested that NEDD9 could be used as prognostic molecular marker to be applied in the clinical setting to diagnosis, evaluating patient’s outcome (prognosis and recurrence) for GC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

NEDD9:

Neural precursor cell expressed developmentally down-regulated 9

GC:

Gastric carcinoma/cancer

PCHNT:

Paracancerous histological normal tissue

BCAR1:

Breast cancer anti-estrogen resistance 1

TNM:

Tumor node metastasis

References

  1. Jackson CB, Giraud AS. STAT3 as a prognostic marker in human gastric cancer. J Gastroenterol Hepatol. 2009;24:505–7.

    Article  PubMed  Google Scholar 

  2. Howlett M, Menheniott TR, Judd LM, Giraud AS. Cytokine signalling via gp130 in gastric cancer. Biochim Biophys Acta. 2009;1793:1623–33.

    Article  CAS  PubMed  Google Scholar 

  3. Ahn HS, Lee HJ, Yoo MW, et al. Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg. 2011;98:255–60.

    Article  CAS  PubMed  Google Scholar 

  4. Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun. 1992;185:1155–61.

    Article  CAS  PubMed  Google Scholar 

  5. Law SF, Estojak J, Wang B, Mysliwiec T, Kruh GD, Golemis EA. Human enhancer of filamentation 1 (NEDD9), a novel p130Cas-like docking protein, associates with FAK, and induces pseudohyphal growth in yeast. Mol Cell Biol. 1996;16:3327–37.

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Seo S, Ichikawa M, Kurokawa M. Structure and function of Cas-L and integrin-mediated signaling. Crit Rev Immunol. 2006;26:391–406.

    Article  CAS  PubMed  Google Scholar 

  7. O’Neill GM, Fashena SJ, Golemis EA. Integrin signaling: a new Cas(t) of characters enters the stage. Trends Cell Biol. 2000;10:111–9.

    Article  PubMed  Google Scholar 

  8. Pugacheva EN, Golemis EA. NEDD9-aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks. Cell Cycle. 2006;5:384–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.

    Article  CAS  PubMed  Google Scholar 

  10. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.

    Article  CAS  PubMed  Google Scholar 

  11. Thiery JP, Chopin D. Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev. 1999;18:31–42.

    Article  CAS  PubMed  Google Scholar 

  12. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Woz-niak AJ, Weiss GR, Moore DF, Israel VK, Livings-ton RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–8.

    CAS  PubMed  Google Scholar 

  13. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341–53.

    Article  PubMed  Google Scholar 

  14. Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, et al. NEDD9 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene. 2006;25:1721–32.

    Article  CAS  PubMed  Google Scholar 

  15. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006;125:1269–81.

    Article  CAS  PubMed  Google Scholar 

  16. Hashemi MR, Rahnavardi M, Bikdeli B, Dehghani Zahedani M, Iranmanesh F. Touch cytology in diagnosing Helicobacter pylori: comparison of fourstaining methods. Cytopathology. 2008;19:179–84.

    Article  CAS  PubMed  Google Scholar 

  17. Tian XY, Zhu H, Zhao J, She Q, Zhang GX. Diagnostic performance of urea breath test, rapid urea test, and histology for Helicobacter pylori infection in patients with partial gastrectomy: a meta-analysis. J Clin Gastroenterol. 2012;46:285–92.

    Article  PubMed  Google Scholar 

  18. Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, et al. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol. 2001;3:128–33.

    Article  CAS  PubMed  Google Scholar 

  19. Shitara K, Mizota A, Yatabe Y, Kondo C, Nomura M, et al. Lapatinib plus trastuzumab for a patient with heavily pretreated gastric cancer that progressed after trastuzumab. Jpn J Clin Oncol. 2011;41(5):663–5.

    Article  PubMed  Google Scholar 

  20. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes—a systematic review. Int J Cancer. 2012;130(12):2845–56.

    Article  CAS  PubMed  Google Scholar 

  21. Izumchenko E, Singh MK, Plotnikova OV, et al. NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res. 2009;69:7198–206.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–8.

    Article  CAS  PubMed  Google Scholar 

  23. Fashena SJ, Einarson MB, O’Neill GM, Patriotis CP, Golemis EA. Dissection of NEDD9-dependent functions in motility and transcriptional regulation. J Cell Sci. 2002;115:99–111.

    CAS  PubMed  Google Scholar 

  24. Seventer GA, Salman HJ, Law SF, et al. Focal adhesion kinase regulates beta1 integrin-dependent T cell migration through an HEF1 effector pathway. Eur J Immunol. 2001;31:1417–27.

    Article  PubMed  Google Scholar 

  25. Dadke D, Jarnik M, Pugacheva EN, Singh MK, Golemis EA. Deregulation of NEDD9 impairs M-phase progression by disrupting the RhoA activation cycle. Mol Biol Cell. 2006;17:1204–17.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. O’Neill GM, Golemis EA. Proteolysis of the docking protein NEDD9 and implications for focal adhesion dynamics. Mol Cell Biol. 2001;21:5094–108.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Simpson KJ, Selfors LM, Bui J, et al. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol. 2008;10:1027–38.

    Article  CAS  PubMed  Google Scholar 

  28. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518–24.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Chung HW, Noh SH, Lim JB. Analysis of demographic characteristics in 3242 young age gastric cancer patients in Korea. World J Gastroenterol. 2010;16:256–63.

    Article  PubMed  Google Scholar 

  30. Kim DY, Joo JK, Ryu SY, et al. Clinicopathologic characteristics of gastric carcinoma in elderly patients: a comparison with young patients. World J Gastroenterol. 2005;11:22–6.

    PubMed  Google Scholar 

  31. Chung HW, Park SW, Chung JB, et al. Differences in genetic expression profiles between young-age and old-age gastric adenocarcinoma using cDNA microarray for endocrine disruptor study. Oncol Rep. 2004;12:33–9.

    CAS  PubMed  Google Scholar 

  32. Masuda G, Tokunaga A, Shirakawa T, et al. Helicobacter pylori infection, but not genetic polymorphism of CYP2E1, is highly prevalent in gastric cancer patients younger than 40 years. Gastric Cancer. 2007;10:98–103.

    Article  PubMed  Google Scholar 

  33. Kokkola A, Valle J, Haapiainen R, et al. Helicobacter pylori infection in young patients with gastric carcinoma. Scand J Gastroenterol. 1996;31:643–7.

    Article  CAS  PubMed  Google Scholar 

  34. Guerrero MS, Parsons JT, et al. Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton. Genes Cancer. 2012;3(5–6):371–81.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The research was supported by the National Natural Science Foundation of China (No. 30771126).

Conflict of interest

The authors declare that they have no conflict of interests.

Author information

Authors and Affiliations

  1. Department of General Surgery, Affiliated Hospital of Nantong University, No. 20, Xisi Road, Nantong, 226001, Jiangsu, People’s Republic of China

    Rongfeng Shi, Junfei Xu, Feiran Wang & Meirong Xu

  2. Nantong Egens Biotechnology Co., Ltd., Nantong, 226010, Jiangsu, People’s Republic of China

    Lei Wang

  3. Department of Thoracic Surgery, Jiangxi Chest Hospital, Nanchang, 330006, Jiangxi, People’s Republic of China

    Tao Wang

Authors
  1. Rongfeng Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junfei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Feiran Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Meirong Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meirong Xu.

Additional information

Rongfeng Shi and Lei Wang have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shi, R., Wang, L., Wang, T. et al. NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma. Med Oncol 31, 852 (2014). https://doi.org/10.1007/s12032-014-0852-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0852-4

Keywords

Search

Navigation